ASX health stocks deliver March quarter progress
It's a key time for investors to zero in on the finer details of ASX-listed firms and get a sense of what is on the horizon.
Here, we wrap up report highlights from four standout stocks in the ASX health sector.
Revenue for Control Bionics' US business over six months to end of March highest since FY23
Best quarter of revenue in Australia since 2022, driven by improved NDIS approval times
Completes investment in Neuro Elite Athletics, the company behind NeuroBounce program for athletes
The assistive technology medical device company reported revenue for its US business over the six months to end of March was the highest since FY23, up 20% over the previous corresponding period (pcp).
Control Bionics attributed the growth to a code approval under the Healthcare Common Procedure Coding System (HCPCS) by the Centers for Medicare & Medicaid Services (CMS) in the US for its key product Neuronode, a watch-like device to assist cognitive people with physical disabilities.
The company said it also achieved a $700,000 in cost savings in North America with margin expansion.
Control Bionics said two well-established US operators now have its NeuroNode devices with their sales team and were actively marketing in the US.
The company also reported its best quarter of revenue in Australia since 2022 with improved NDIS approval times and a strong sales pipeline driving the success.
While the backlog continues to be cleared Control Bionics said it has almost $1 million in applications awaiting NDIS approval.
During the quarter it completed its investment in Neuro Elite Athletics, which is the company behind the NeuroBounce program for athletes.
During the quarter its launch customer Utah Prep Academy in the US delivered strong results, measurably improving explosive power and vertical leap for elite athletes with Control Bionics' NeuroStrip.
A new cloud-deployed version of NeuroStrip has been launched, providing access to a new SaaS revenue stream along with hardware sales.
Cash receipts for the quarter were the highest in 12 months, exceeding $1.6m and up from $1.4m in Q2 FY25, driven by improved sales in the US and Australia.
During the quarter founder Peter Ford stepped down from the board and was replaced by Dr Stephanie Phillips, who has more than three decades of clinical, academic and leadership experience in anaesthesia and critical care.
Control Bionics finished the quarter with cash of $1.7m.
"We are delivering strong sales, cash collection and meaningful progress on our growth initiatives," CEO Jeremy Steele said.
"We've found strong commercial appetite for our core IP, the NeuroNode, through our NeuroNode Only strategy. We've rolled out this technology now to multiple distributors (both in pilot and contract phases) in multiple geographies.'
Developer of a nasal spray-mist erectile dysfunction treatment LTR Pharma successfully holds pre-IND meeting with US FDA
Chief scientific & clinical adviser Professor Eric Chung receives prestigious award for his presentation on SPONTAN
LTR announces in quarter new ED nasal spray targeting the US personalised healthcare sector called ROXUS
The developer of a nasal spray-mist erectile dysfunction treatment said it delivered significant progress across its regulatory, commercial and scientific objectives during the March quarter.
In March, LTR Pharma held a successful pre-IND meeting with the US Food & Drug Administration. Key outcomes included:
Endorsement of its non-clinical (toxicology) and chemistry, manufacturing and controls (CMC) development plans
Agreement on a pivotal efficacy/safety study and a multi-dose pharmacokinetic study; and
Clear guidance on the pathway to market through the 505(b)(2) regulatory process.
Following the meeting LTRPharma has initiated CMC studies with Aptar Pharma, started extractables and leachables studies required for regulatory documentation and developed specific protocols for the upcoming clinical studies.
During the quarter the company's novel intranasal formulation of vardenafil for ED SPONTAN was recognised at the Urological Society of Australia and New Zealand's (USANZ) Annual Scientific Meeting.
Chief scientific and clinical adviser Professor Eric Chung was awarded the BAUS Trophy — the event's highest honour — for his presentation of SPONTAN's clinical results.
LTR Pharma said the scientific recognition, voted on by a panel of leading urologists, reinforces SPONTAN as a best-in-class, fast-acting ED therapy, while also attracting strong international interest from urologists and key opinion leaders.
During the quarter the company announced a new ED nasal spray targeting the US personalised healthcare sector called ROXUS, representing a expansion of the company's product portfolio.
LTR Pharma also continued to expanded its Australian commercial operations during the quarter through several initiatives and partnerships.
Key expenditure for the quarter was continued investment in the joint venture with Restorative Sexual Health for a new online healthcare platform, providing comprehensive men's health services through telehealth.
The company ended the March quarter with cash position of $32.8m.
Lumos revenue of US$3.5 million for Q3 FY25, up 21% compared to the prior quarter
Hologic foetal fibronectin project scope of work expansion was signed and forecast to generate additional fee revenue
FebriDx CLIA Waiver Study continues with around 351 patients tested to-date, including 37 bacterial-positive patients
The developer of rapid point-of-care diagnostic technologies reported revenue of US$3.5m for the quarter, up 21% compared to the prior quarter as it works to build sustainable growth.
Revenue generated during the quarter from the services business was US$2.8m. Lumos said its foetal fibronectin (fFN) development agreement with leading women's health company Hologic (NASDAQ: HOLX) and the intellectual property licensing revenue associated with the Hologic IP deal generated the majority of revenue.
During the quarter the Hologic fFN project scope of work expansion was signed and is forecast to generate an additional US$600,000 to US$800,000 in fee revenue.
Revenue from its products business was US$700,000 for Q3, up 17% on Q2 revenue. Following additional sales in the UK and growing adoption in the US, FebriDx sales continue to grow with revenue increasing 48% on pcp.
Additional FebriDx distribution partnership agreements completed in the US with MedPro Associates and the US Defense Logistics Agency (DLA) during the quarter.
FebriDx CLIA Waiver Study continues with around 351 patients tested to-date, including 37 bacterial-positive patients. Completion of the the study and an application for CLIA waiver labelling for FebriDx with the FDA is forecast by calendar year end.
In late March, Lumos completed and lodged an application with the Australian Government Department of Health and Aged Care for the inclusion of FebriDx on the Medicare Benefits Schedule.
Operating cashflow improved, with an operating cash outflow of US$1.3m, compared with US$3.7m in Q2 FY25.
Lumos ended the quarter with a cash balance of US$4m.
Post quarter Lumos has made significant progress with US Medicare payor coverage for FebriDx, with reimbursement secured with four of the seven Medicare Administration Contractors, and discussions ongoing with the remaining three.
EMvision kicks off pivotal clinical trial for emu bedside brain scanner
Trial will support US FDA de novo clearance for emu device
EMvision undertakes proof-of-concept testing for First Responder scanner
Neuro-diagnostics medical devices company EMvision started its pivotal clinical trial for its first commercial device the emu bedside brain scanner during the March quarter.
The trial is designed to support US FDA de novo (new device) clearance for the emu device, with Royal Melbourne Hospital (RMH) the first of six sites to be activated.
The RMH is a world-class comprehensive stroke centre and home to the Melbourne Brain Centre – the largest brain research collaboration in the southern hemisphere.
An emu device has also been shipped to the first US site, University of Texas Health Science Center at Houston (UTHealth) Medical School and Memorial Hermann-Texas Medical Center (TMC).
After quarter-end, EMvision shipped an emu to the Mayo Clinic in the US, with site initiation and training set for early May.
During the quarter EMvision also undertook proof-of-concept testing of its portable device First Responder to detect strokes and traumatic brain injury.
Under an existing ethics approval, the First Responder device wastested in remote locations, in collaboration with the Royal Flying Doctor Service (RFDS) and the Australian Stroke Alliance (ASA).
EMvision plans to attend several leading industry event to showcase its technology. The company finished the quarter with cash reserves of $12.58m with activities over the remainder of FY25 to be supported by $800,000 of payments under a ASA grant program.
Control Bionics, LTR Pharma, Lumos Diagnostics and EMvision Medical Devices are Stockhead advertisers at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
AU Financial Review
16 hours ago
- AU Financial Review
Sushi Hub sold $200m of sushi last year. Now it wants a $1b valuation
Sushi Hub chief executive Raymond Chen has a figure in mind: $1 billion. That is the valuation the founder of the fast-growing Japanese food chain wants to reach before he considers selling a stake. That bullish target is based on ambitions that the Australian sushi chain can become the next Guzman Y Gomez, which hit the ASX in June last year and has been worth as much as $3.75 billion at its peak. Sushi Hub has gone from strength to strength, opening almost 70 stores during the pandemic due to its owners being flush with cash – unlike most traditional hospitality businesses – and it's on track to open its 200th store by year's end.
News.com.au
a day ago
- News.com.au
Stock Tips: A gold player, a blue-chip beast and bikes rev up this week
It's no easy gig analysing share prices and company performance but somebody's got to do it. Every week two experts from our Share Tips columnist pool give us their recommendations. Andrew Eddy – Morgans Financial BUY Minerals 260 (ASX:MI6) Offers significant gold resource growth potential, clear M&A appeal and a path to production. Not without risk but seeing significant upside potential. Motorcycle Holdings (ASX:MTO) Has acquired profitable dealerships, expanded into new markets and strengthened its e-commerce capabilities, positioning itself for significant growth. HOLD Transurban Group (ASX:TCL) Offers stable returns with high-quality toll road assets, driven by population growth, economic development and strong pricing power through toll escalations. James Hardie (ASX:JHX) The highest quality building products business on the ASX, with strong returns on capital and a dominant market position. Just need to see an improving housing outlook in the US to become more bullish. SELL Santos (ASX:STO) Investors might consider taking some money off the table with Santos with limited upside to bid price but there are significant risks and hurdles for a deal to be completed. Cochlear (ASX:COH) Company recently downgraded guidance on slower growth in services and Cochlear Implant uptake. Still a quality stock but further downside earnings risks remain. Dylan Evans – Catapult Wealth BUY Wesfarmers (ASX:WES) Has reported good results in difficult conditions for retail. Should continue to do well as consumers benefit from easing inflation and falling rates. National Storage REIT (ASX:NSR) Well placed for growth, with modest debt and less than a 20% share of the fractured self-storage market. The recent takeover bid for its listed competitor Abacus is also positive for valuation. HOLD Telstra (ASX:TLS) Finally finding some momentum and growth across its two core divisions, mobile and InfraCo. Its leading mobile network remains a valuable asset, one which Telstra should be able to capture more value from. Challenger (ASX:CGF) Has been a disappointing investment for many years, but there are some positive tailwinds emerging. These include super moving from accumulation to retirement income, and government requirements for the development of alternative retirement income products. SELL Vicinity Centres (ASX:VCX) Operates a portfolio of well-located shopping centers across Australia. Occupancy is high but may see some pressure from a trend of retailers consolidating smaller stores into larger flagship locations. Iluka Resources (ASX:ILU) Iluka's move into rare earths represents a new direction for the company that will demand significant capital and is unlikely to contribute to earnings for many years. In the meantime, the core mineral sands business is volatile and uncertain.
News.com.au
2 days ago
- News.com.au
Aussie buyers shrug off interest rate fears
Interest rates are no longer the biggest factor holding buyers back, with a new national survey showing nearly half of Australians who bought or sold in the past year weren't influenced by rates at all. The 2025 State of Real Estate report by proptech firm InfoTrack found only 29 per cent of respondents said rates had a significant or considerable impact on their decision — a sharp drop from 62 per cent in 2024. 'In last year's report, two-thirds cited interest rates as a major factor influencing their decision-making process. But in 2025, that number has dropped significantly,' InfoTrack's head of property Australia, Lee Bailie, said. 'The finding challenges the idea that interest rates are stopping people from buying or selling. Instead, Australians are staying active in the market but adapting to current conditions.' For those affected by rates, the biggest impacts were on budget (43 per cent) and the type of property they could afford (32 per cent). The move comes as the ASX traded at a 51 per cent expectation of a 0.5 percentage point cut to the official cash rate to 3.35 per cent when the Reserve Bank of Australia (RBA) meets Tuesday. It's a bolder prediction than any of Australia's big 4 banks, with CBA, NAB, Westpac and ANZ all sitting on a 0.25pp decrease. Bendigo Bank's chief economist David Robertson predicted quarterly cuts down to around 3-3.25 per cent by February 2026. 'A month of from the RBA surprising markets by keeping rates on hold, insisting they wanted more evidence of moderating inflation, we'e seen nothing but confirmation that inflation is at or below its target of 2.5 per cent, and that the risks of any rebound in underlying inflation have receded further,' Mr Robertson said. Brisbane property boom hits the skids InfoTrack's report shows affordability has now overtaken rates as the biggest hurdle, with 27 per cent of participants nominating property prices as their greatest obstacle, up six per cent from 2024 and the largest rise of any challenge. More than half (54 per cent) said prices had a significant or major impact on their decision, while 69 per cent said it determined where they bought. The report also found 59 per cent of buyers and sellers completed their transaction within three months, with regional areas proving especially popular with NSW buyers seeking affordability, space and flexibility through hybrid work.
